Scientific Programme Wednesday, 25 October 2017

1 Scientific ProgrammeWednesday, 25 October 2017 Teaching Courses, Hall C08:30 - 10:00 Teaching Course 1: Disease modifying Fox (Cleveland, US)L. Kappos (Basel, CH)08:30 - 09:001 DMTs 2017 : new MS treatments and updates on established treatments Fox (Cleveland, US)09:00 - 09:302 Defining what is working: choosing when and how to escalate therapy L. Kappos (Basel, CH)09:30 - 10:003 Clinical trial statistics: pearls and lessons from MS trials Sormani (Genoa, IT)Teaching Courses, Hall D08:30 - 10:00 Teaching Course 2: MS and reproduction: fromcontraception to post conception reproductiveepidemiology and planning a pregnancy in women with MSChairsK. Hellwig (Bochum, DE)A. Langer Gould (Pasadena, US)08:30 - 09:004 Counselling of women with MS in the reproductive age fromcontraception to conception-general recommendations Houtchens (Brookline, US)09:00 - 09:305 Multiple sclerosis and pregnancy management in 2017 : medications andlactation K. Hellwig (Bochum, DE)09:30 - 10:006 Reproductive epidemiology in multiple sclerosis (puberty, pregnancy,breastfeeding, assisted reproductive techniques and menopause) A.

2 Langer Gould (Pasadena, US)Teaching Courses, Hall E08:30 - 10:00 Teaching Course 5: Biomarkers in MSChairsB. Hemmer (Munich, DE)M. Comabella (Barcelona, ES)Page 1 / 108 Scientific Programme08:30 - 09:007 General considerations to develop and use biomarkers in MS B. Hemmer (Munich, DE)09:00 - 09:308 Biomarkers of neuroinflammation M. Comabella (Barcelona, ES)09:30 - 10:009 Biomarkers of CNS neurodegeneration M. Otto (Ulm, DE)Teaching Courses, Hall F08:30 - 10:00 Teaching Course 4: Myelin repair: Scientific backgroundand clinical implicationsChairsB. Stankoff (Paris, FR)L. Leocani (Milan, IT)08:30 - 09:0010 Mechanisms leading to success or failure of myelin repair in the centralnervous system R. Franklin (Cambridge, UK)09:00 - 09:3011 Evaluation of myelin repair: electrophysiological outcomes L. Leocani (Milan, IT)09:30 - 10:0012 Evaluation of myelin repair: imaging outcomes B. Stankoff (Paris, FR)Teaching Courses, Hall G08:30 - 10:00 Teaching Course 3: Advanced MS genetics andimmunologyChairsR.

3 Liblau (Toulouse, FR)F. Zipp (Mainz, DE)08:30 - 09:0013 The MS genomic map: translating genetic architecture into a roadmap fordissecting neuroimmune mechanisms P. De Jager (New York, US)09:00 - 09:3014 Immunology of MS: how does the pathogenic adaptive immune responsedevelop? R. Liblau (Toulouse, FR)09:30 - 10:0015 Immunology of MS: innate and adaptive immune events within the CNS F. Zipp (Mainz, DE)Page 2 / 108 Scientific ProgrammeTeaching Courses, Hall C10:30 - 12:00 Teaching Course 6: Controversy in Miller (New York, US)X. Montalban (Barcelona, ES)10:30 - 11:0016 Case 1: relapsing MS Miller (New York, US)11:00 - 11:3017 Case 2: progressive MS X. Montalban (Barcelona, ES)11:30 - 12:0018 Case 3: neuromyelitis optica spectrum disorder (NMOSD) I. Katz Sand (New York, US)Teaching Courses, Hall D10:30 - 12:00 Teaching Course 7: Symptomatic therapy of gaitdisturbances, spasticity, bladder dysfunction andparoxysmal symptomsChairsT. Berger (Innsbruck, AT)M. Pakzad (London, UK)10:30 - 11:0019 Bladder dysfunction: pitfalls and challenges M.

4 Pakzad (London, UK)11:00 - 11:3020 Spasticity and walking impairment: early to recognise and to treat C. Oreja-Guevara (Madrid, ES)11:30 - 12:0021 Paroxysmal symptoms: often neglected, but treatment needed T. Berger (Innsbruck, AT)Teaching Courses, Hall E10:30 - 12:00 Teaching Course 8: Brain atrophy in clinical practice:evidence base and barriers to implementationChairsF. Barkhof (Amsterdam, NL)J. Sastre-Garriga (Barcelona, ES)10:30 - 11:0022 Natural history & clinical relevance of brain volume changes in patientswith MS F. Barkhof (Amsterdam, NL)11:00 - 11:3023 Value of brain volume changes to predict treatment response in patientswith MS J. Sastre-Garriga (Barcelona, ES)Page 3 / 108 Scientific Programme11:30 - 12:0024 Barriers to brain volume measurement in the real world M. Battaglini (Siena, IT)Teaching Courses, Hall F10:30 - 12:00 Teaching Course 9: Amato (Florence, IT)J. DeLuca (West Orange, US)10:30 - 11:0025 Epidemiology of cognitive impairment: an update Amato (Florence, IT)11:00 - 11:3026 Current approaches to management J.

5 DeLuca (West Orange, US)11:30 - 12:0027 Cognition as a clinical outcome measure in clinical trials on DMDs Benedict (Buffalo, US)Teaching Courses, Hall G10:30 - 12:00 Teaching Course 10: Progressive multiple sclerosis andthe relationship to relapsing disease - how neuroglialinteractions underlie the pathogenesis and treatmentChairsS. Ludwin (Kingston, CA)H. Lassmann (Wien, AT)10:30 - 11:0028 Oxidative injury to glial cells and neurons as a basis for progressivedisease H. Lassmann (Wien, AT)11:00 - 11:3029 Astrocyte patho-biology and interactions with other glia and neurons inthe development of PMS S. Ludwin (Kingston, CA)11:30 - 12:0030 Targeting glia as the basis of treating progressive PMS Yong (Calgary, CA)Satellite Symposia, Hall B12:30 - 13:30 European Charcot Foundation - Reconsidering the conceptof induction therapyChairsG. Comi (Milan, IT)Page 4 / 108 Scientific Programme12:30 - 12:5031 The concept Freedman (Ottawa, CA)12:50 - 13:1032 The evidence G. Edan (Rennes, FR)13:10 - 13:3033 The problems and the future perspectives Hartung (Duesseldorf, DE)Teaching Courses, Hall C12:30 - 14:00 Teaching Course 11: Differential diagnosesChairsS.

6 Fredrikson (Stockholm, SE)A. Siva (Istanbul, TR)12:30 - 13:0034 Diagnostic and differential diagnostic dilemmas in MS S. Fredrikson (Stockholm, SE)13:00 - 13:3035 MRI-diagnostic possibilities and pitfalls A. Siva (Istanbul, TR)13:30 - 14:0036 NMOSD including antiMOG related disorders as differential diagnoses toMS B. Weinshenker (Rochester, US)Teaching Courses, Hall D12:30 - 14:00 Teaching Course 12: Neuromyelitis optica Wingerchuk (Scottsdale, US)K. Fujihara (Sendai, JP)12:30 - 13:0037 Update on pathogenesis of NMOSD K. Fujihara (Sendai, JP)13:00 - 13:3038 Diagnostic issues with AQP4-IgG-seropositive and -seronegative NMOSD Wingerchuk (Scottsdale, US)13:30 - 14:0039 Optimising treatment of NMOSD in various situations R. Marignier (Lyon, FR)Page 5 / 108 Scientific ProgrammeTeaching Courses, Hall E12:30 - 14:00 Teaching Course 13: Imaging the non-MS lesion in MSChairsD. Reich (Bethesda, US)A. Rovira (Barcelona, ES)12:30 - 13:0040 Atypical imaging presentations of MS and other idiopathic demyelinatingdiseases A.

7 Rovira (Barcelona, ES)13:00 - 13:3041 Imaging the complications of MS therapies D. Reich (Bethesda, US)13:30 - 14:0042 The central vein sign on MRI P. Sati (Bethesda, US)Teaching Courses, Hall F12:30 - 14:00 Teaching Course 14: OCT in clinical practiceChairsS. Galetta (New York, US)L. Balcer (New York, US)12:30 - 13:0043 OCT in MS: what have we learned so far? L. Balcer (New York, US)13:00 - 13:3044 OCT in MS: what is new? S. Saidha (Baltimore, US)13:30 - 14:0045 OCT in the clinic: case by case S. Galetta (New York, US)Teaching Courses, Meeting Room 31512:30 - 14:00 Case-based Teaching Course 15: Paediatric MSChairsB. Banwell (Philadelphia, US)K. Deiva (Paris, FR)12:30 - 13:1546 Case presentation 1 B. Banwell (Philadelphia, US)13:15 - 14:0047 Case presentation 2 K. Deiva (Paris, FR)Page 6 / 108 Scientific ProgrammeParallel Sessions, Hall B14:00 - 15:30 Parallel Session 1: Prevalence and phenotype evolution ofMS in different continentsChairsP. Duquette (Montr al, CA) Sahraian (Tehran, IR)14:00 - 14:2048 Asia Y.

8 Takashi (Tokyo, JP)14:20 - 14:4049 Africa-Middle East R. Gouider (Manouba, TN)14:40 - 15:0050 Latin America L. Negrotto (Buenos Aires, AR)15:00 - 15:2051 Australia and New Zealand H. Butzkueven (Melbourne, AU)15:20 - 15:3052 The clinical course, therapeutic responses, and outcomes in relapsingMOG antibody-associated demyelination S. Ramanathan (Sydney, AU)Young Scientific Investigators Sessions, Hall C14:00 - 15:30 Young Scientific Investigators' Session 1 ChairsP. Calabresi (Baltimore, US)V. Zujovic (Paris, FR)14:00 - 14:1553 Brain atrophy rates in multiple sclerosis changes along disease courseare sensitive to image processing method: not ready for NEDA-4 yet? M. Andorr (Barcelona, ES)14:15 - 14:3054 Altered default-mode network dynamics in cognitively impaired MSpatients Eijlers (Amsterdam, NL)14:30 - 14:4555 Ganglion cell layer atrophy starts one week after onset of acute opticneuritis and progress over 18 months Martinez-Lapiscina (Barcelona, ES)14:45 - 15:0056 Predicting performance improvements with visuomotor training in MSusing a multi-modal clinical and neuroimaging approach I.

9 Lipp (Cardiff, UK)15:00 - 15:1557 Enlargement of white matter MS lesions is associated with lesionalmicroglial activation measured in vivo C. Benoit (Paris, FR)Page 7 / 108 Scientific Programme15:15 - 15:3058 Independent contributions of cervical cord lesions and thalamic,cerebellar, and putaminal volumes to upper extremity function in earlymultiple sclerosis A. Harel (New York, US)Nurses Sessions, Hall E14:15 - 15:30 Nurses' Session 1: Impact of MS nursing across EuropeChairsA. Winslow (Dublin, IE)14:15 - 14:2559 Introduction and welcome D. Miller (London, UK) A. Winslow (Dublin, IE)14:25 - 14:4060MS Nurse Pro Launch of the rehabilitation module N. Abel (Birmingham, UK)14:40 - 15:3061 Core challenges, opportunities and impact of MS nursing across Europe(panel-debate) A. Perrin Ross (Maywood, US) V. Matthews (Herts, UK) K. Harrison (Blaricum, NL) R. Motta (Genoa, IT) J. Hlavacova (Prague, CZ) C. Iakob (Bucharest, RO) J. Sastre-Garriga (Barcelona, ES)Teaching Courses, Meeting Room 31514:15 - 15:45 Case-based Teaching Course 16: Induction treatment invery active multiple sclerosis: why, how, when?

10 ChairsG. Edan (Rennes, FR)E. Le Page (Rennes, FR)14:15 - 15:0062 Case presentation 1 G. Edan (Rennes, FR)15:00 - 15:4563 Case presentation 2 E. Le Page (Rennes, FR)Page 8 / 108 Scientific ProgrammeTeaching Courses, Meeting Room 313/31414:15 - 15:45 Case-based Teaching Course 17: Definition of non-respondersChairsM. Tintor (Barcelona, ES)A. Ruet (Bordeaux, FR)14:15 - 15:0064 Case presentation 1: failing to first line treatment: NEDA vs MEDA A. Ruet (Bordeaux, FR)15:00 - 15:4565 Case presentation 2: definition on treatment response in second linetreatment: how to face pregnancy desire while being on treatment M. Tintor (Barcelona, ES)Teaching Courses, Meeting Room 311/31214:15 - 15:45 Case-based Teaching Course 18: Progressive MS: whom totreat, with what and for how long? Cree (San Francisco, US)F. Paul (Berlin, DE)14:15 - 15:0066 Progressive MS: whom to treat, with what and for how long? Cree (San Francisco, US)15:00 - 15:4567 Case presentation 2 F. Paul (Berlin, DE)Hot Topic Sessions, Hall B16:00 - 16:45 Hot Topic 1: Progressive MS alliance: what s Carroll (Nedlands, AU)R.